| Literature DB >> 12706675 |
Patricia E Shewen1, Chiang W Lee, Ann Perets, Douglas C Hodgins, Katherine Baldwin, Reggie Y C Lo.
Abstract
Secreted recombinant sialoglycoprotease fusion protein (Gcp-F) of Mannheimia (Pasteurella) haemolytica A1 was examined for its ability to protect cattle from experimental challenge with M. haemolytica A1. Five M. haemolytica vaccines were compared including Gcp-F, logarithmic phase culture supernate (Presponse) and Presponse enriched with Gcp-F, recombinant leukotoxin (rLkt) or both. All calves receiving Gcp-F had significant serum antibody responses to this antigen, measured by ELISA, prior to challenge. Those vaccinated with Gcp-F alone had significantly lower percent pneumonic tissue than unvaccinated controls and a trend (P=0.085, one-tailed test) to lower clinical scores. Calves receiving Presponse with Gcp-F and rLkt had lower percent pneumonic tissue than those receiving Presponse alone, and calves receiving Presponse enriched with Gcp-F and/or rLkt had lower mean clinical scores, but the differences were not significant. This trial demonstrates the protective capacity of sialoglycoprotease. While, remarkably, recombinant Gcp-F provided some protection alone the results support its practical potential as a component of a multiple antigen vaccine.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12706675 DOI: 10.1016/s0264-410x(03)00002-1
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641